TY  - JOUR
AU  - Lopez-Beltran, Antonio
AU  - Cimadamore, Alessia
AU  - Blanca, Ana
AU  - Massari, Francesco
AU  - Vau, Nuno
AU  - Scarpelli, Marina
AU  - Cheng, Liang
AU  - Montironi, Rodolfo
PY  - 2021
DO  - 10.3390/cancers13010131
SN  - 2072-6694
UR  - https://hdl.handle.net/10668/28301
T2  - Cancers
AB  - A number of immune checkpoint inhibitors (ICIs) have been approved as first-line therapy in case of cisplatin-ineligible patients or as second-line therapy for patients with metastatic urothelial carcinoma (mUC) of the bladder. About 30% of patients...
LA  - en
KW  - Atezolizumab
KW  - Avelumab
KW  - Durvalumab
KW  - Nivolumab
KW  - PD-1
KW  - PD-L1
KW  - Pembrolizumab
KW  - biomarker
KW  - bladder cancer
KW  - immune checkpoint inhibitor
KW  - immunotherapy
KW  - tumor mutation burden
KW  - urothelium
KW  - variant histology
TI  - Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.
TY  - research article
VL  - 13
ER  -